ProCE Banner Activity

Practical Guidance on Optimizing CLL Care in the Era of Molecular Therapies

Slideset Download
Download these slides to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.

Released: July 17, 2019

Expiration: July 15, 2020

No longer available for credit.

Share

Faculty

Emily Bucholtz

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Nichole Fisher

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics AbbVie

Verastem Oncology

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon